| cfa05206 |
MiRNAs in cancer |
31 |
139 |
22.30% |
2.70E-05 |
| cfa05200 |
Pathways in cancer |
62 |
393 |
15.78% |
4.29E-04 |
| cfa04010 |
MAPK signaling pathway |
43 |
252 |
17.06% |
6.55E-04 |
| cfa04060 |
Cytokine–cytokine receptor interaction |
38 |
216 |
17.59% |
7.35E-04 |
| cfa04151 |
PI3K-Akt signaling pathway |
53 |
334 |
15.87% |
9.73E-04 |
| cfa03060 |
Protein export |
8 |
23 |
34.78% |
1.55E-03 |
| cfa04933 |
AGE-RAGE signaling pathway in diabetic complications |
21 |
102 |
20.59% |
1.57E-03 |
| cfa04510 |
Focal adhesion |
35 |
204 |
17.16% |
1.84E-03 |
| cfa04810 |
Regulation of actin cytoskeleton |
36 |
212 |
16.98% |
1.92E-03 |
| cfa04974 |
Protein digestion and absorption |
18 |
84 |
21.43% |
2.08E-03 |
| cfa04062 |
Chemokine signaling pathway |
30 |
172 |
17.44% |
2.94E-03 |
| cfa04722 |
Neurotrophin signaling pathway |
22 |
120 |
18.33% |
5.56E-03 |
| cfa04320 |
Dorsoventral axis formation |
8 |
28 |
28.57% |
6.14E-03 |
| cfa05205 |
Proteoglycans in cancer |
32 |
197 |
16.24% |
6.65E-03 |
| cfa04666 |
Fc γ R-mediated phagocytosis |
17 |
88 |
19.32% |
8.25E-03 |
| cfa04068 |
FoxO signaling pathway |
23 |
132 |
17.42% |
8.72E-03 |
| cfa04668 |
TNF signaling pathway |
19 |
105 |
18.10% |
1.10E-02 |
| cfa04670 |
Leukocyte transendothelial migration |
21 |
120 |
17.50% |
1.13E-02 |
| cfa04360 |
Axon guidance |
22 |
128 |
17.19% |
1.19E-02 |
| cfa04550 |
Signaling pathways regulating pluripotency of stem cells |
23 |
138 |
16.67% |
1.47E-02 |
| cfa05212 |
Pancreatic cancer |
13 |
65 |
20.00% |
1.48E-02 |
| cfa00310 |
Lysine degradation |
11 |
52 |
21.15% |
1.60E-02 |
| cfa04115 |
p53 signaling pathway |
13 |
66 |
19.70% |
1.67E-02 |
| cfa04350 |
TGF-β signaling pathway |
15 |
82 |
18.29% |
2.04E-02 |
| cfa04512 |
ECM–receptor interaction |
15 |
82 |
18.29% |
2.04E-02 |
| cfa05222 |
Small cell lung cancer |
15 |
84 |
17.86% |
2.50E-02 |
| cfa04919 |
Thyroid hormone signaling pathway |
19 |
115 |
16.52% |
2.72E-02 |
| cfa02010 |
ABC transporters |
9 |
43 |
20.93% |
2.99E-02 |
| cfa05166 |
HTLV-I infection |
35 |
246 |
14.23% |
3.26E-02 |
| cfa04064 |
NF-κB signaling pathway |
15 |
87 |
17.24% |
3.32E-02 |
| cfa05202 |
Transcriptional misregulation in cancer |
24 |
158 |
15.19% |
3.59E-02 |
| cfa05220 |
Chronic myeloid leukemia |
13 |
73 |
17.81% |
3.61E-02 |
| cfa05146 |
Amoebiasis |
16 |
96 |
16.67% |
3.77E-02 |
| cfa04917 |
Prolactin signaling pathway |
13 |
74 |
17.57% |
3.98E-02 |
| cfa04144 |
Endocytosis |
35 |
252 |
13.89% |
4.42E-02 |
| cfa04620 |
Toll-like receptor signaling pathway |
16 |
98 |
16.33% |
4.44E-02 |
| cfa04014 |
Ras signaling pathway |
31 |
220 |
14.09% |
4.74E-02 |
| cfa00603 |
Glycosphingolipid biosynthesis – globo series |
4 |
14 |
28.57% |
4.96E-02 |
